A Study of Psychedelics in Healthy Older Adults With Low Well-being
NCT07386730
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being. The main questions it aims to answer are, does psilocybin: Acutely increase complexity of EEG activity in older adults with low well-being, as modulated by the presence of biomarkers of Alzheimer's disease (AD) pathology. Longitudinally decrease plasma markers of neuroinflammation, as modulated by the presence of biomarkers of AD pathology.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Anhedonia in Healthy Volunteers
- Older Adults (50-90 Years)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Jennifer Mitchell
- Last updated on ClinicalTrials.gov
- September 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco, Sandler Neuroscience Building · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.